ClinicalTrials.gg
CompletedNCT00536913SpacerUpdated Apr 6, 2012Results posted

Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma

A Phase 3 interventional study of Budesonide/formoterol pMDI 40/2.25ug + spacer and Budesonide/formoterol pMDI 40/2.25 ug in Asthma, sponsored by AstraZeneca. Completed at 11 sites in 3 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2012-04-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
149th of 248
107 · median 175
Started
2007
with 17 others
Phase 3
121 of 359
6 open now
Registered
69th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 149th largest by enrollment of the 248 interventional ones that give a count, is one of 18 that started in 2007, is one of 121 in phase 3, and was the 69th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of the study is to compare Symbicort pMDI with and without spacer in terms of steroid potency, improvement of lung function and asthma symptoms in children with asthma (6-11 years).

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Symbicort pMDI
  • spacer
  • children
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children 6-11 years, diagnosed asthma treated
  • 6 months, PEF
  • 50% of predicted normal value pre-bronchodilator

Exclusion criteria

Exclusion Criteria:

  • current systemic glucocorticosteroids usage
  • current respiratory infection
  • any significant disease or disorder as judged by investigator
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    With Spacer

    Budesonide/formoterol pMDI 40/2.25ug + spacer

    Drug: Budesonide/formoterol pMDI 40/2.25ug + spacer

  • Experimental
    Without Spacer

    Budesonide/formoterol pMDI 40/2.25 ug

    Drug: Budesonide/formoterol pMDI 40/2.25 ug

Interventions

  • DrugBudesonide/formoterol pMDI 40/2.25ug + spacer
  • DrugBudesonide/formoterol pMDI 40/2.25 ug
06

What researchers measure

Primary outcomes

  1. Urinary Free Cortisol (UFC)

    Ratio between the value at the end of treatment and the value at start of treatment, including only patients with values at both baseline and end of treatment

    Time frame: At baseline and 4 weeks

Secondary outcomes

  1. Forced Expiratory Volume in 1 Second (FEV1)

    Changes in FEV1 from baseline to the mean value at 2 weeks to 4 weeks with the baseline value as a covariate.

    Time frame: At baseline, at 2 weeks and 4 weeks

  2. Morning Peak Expiratory Flow (mPEF)

    Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry were estimated using linear interpolation.

    Time frame: Daily during run-in and daily during treatment period of 6 weeks

  3. Evening Peak Expiratory Flow (ePEF)

    Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation. Missing data between the first and last entry were estimated using linear interpolation.

    Time frame: Daily during run-in and daily during treatment period of 6 weeks

  4. Asthma Symptoms at Night

    Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

    Time frame: Daily during run-in and daily during treatment period of 6 weeks

  5. Asthma Symptoms at Day

    Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

    Time frame: Daily during run-in and daily during treatment period of 6 weeks

  6. Percentage of Nights With Awakenings Due to Asthma

    Change in Percentage of nights with awakenings, average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.

    Time frame: Daily during run-in and daily during treatment period of 6 weeks

  7. Use of Rescue Medication at Night

    Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.

    Time frame: Daily during run-in and daily during treatment period of 6 weeks

  8. Use of Rescue Medication at Day

    Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.

    Time frame: Daily during run-in and daily during treatment period of 6 weeks

07

Results

Posted Feb 27, 2012

Participant flow

137 subjects enrolled; 30 non randomised: 26 failed inclusion criteria, 2 voluntary discontinuations, 1 incorrect enrolment, 1 adverse event. 107 subjects were randomised

Participant flow — Overall Study
MilestoneWith SpacerWithout Spacer
Started5552
Completed5552
Not completed00

Outcome measures

PrimaryUrinary Free Cortisol (UFC)

Ratio between the value at the end of treatment and the value at start of treatment, including only patients with values at both baseline and end of treatment

Time frame:
At baseline and 4 weeks
Reported as:
Geometric mean · Ratio
Urinary Free Cortisol (UFC)
RatioWith SpacerWithout Spacer
Urinary Free Cortisol (UFC)0.86 (0.20 to 2.4)1.03 (0.12 to 5.4)
SecondaryForced Expiratory Volume in 1 Second (FEV1)

Changes in FEV1 from baseline to the mean value at 2 weeks to 4 weeks with the baseline value as a covariate.

Time frame:
At baseline, at 2 weeks and 4 weeks
Reported as:
Mean · Liters
Forced Expiratory Volume in 1 Second (FEV1)
LitersWith SpacerWithout Spacer
Forced Expiratory Volume in 1 Second (FEV1)0.17 ± -0.380.14 ± -0.34
SecondaryMorning Peak Expiratory Flow (mPEF)

Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry were estimated using linear interpolation.

Time frame:
Daily during run-in and daily during treatment period of 6 weeks
Reported as:
Mean · Liters/min
Morning Peak Expiratory Flow (mPEF)
Liters/minWith SpacerWithout Spacer
Morning Peak Expiratory Flow (mPEF)28.70 ± 24.619.50 ± 25.1
SecondaryEvening Peak Expiratory Flow (ePEF)

Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation. Missing data between the first and last entry were estimated using linear interpolation.

Time frame:
Daily during run-in and daily during treatment period of 6 weeks
Reported as:
Mean · Liters/min
Evening Peak Expiratory Flow (ePEF)
Liters/minWith SpacerWithout Spacer
Evening Peak Expiratory Flow (ePEF)27.00 ± 27.715.30 ± 23.0
SecondaryAsthma Symptoms at Night

Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

Time frame:
Daily during run-in and daily during treatment period of 6 weeks
Reported as:
Mean · Units on a scale
Asthma Symptoms at Night
Units on a scaleWith SpacerWithout Spacer
Asthma Symptoms at Night-0.20 ± 0.46-0.21 ± 0.39
SecondaryAsthma Symptoms at Day

Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

Time frame:
Daily during run-in and daily during treatment period of 6 weeks
Reported as:
Mean · Units on a scale
Asthma Symptoms at Day
Units on a scaleWith SpacerWithout Spacer
Asthma Symptoms at Day-0.25 ± 0.43-0.28 ± 0.41
SecondaryPercentage of Nights With Awakenings Due to Asthma

Change in Percentage of nights with awakenings, average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.

Time frame:
Daily during run-in and daily during treatment period of 6 weeks
Reported as:
Mean · Percentage of nights
Percentage of Nights With Awakenings Due to Asthma
Percentage of nightsWith SpacerWithout Spacer
Percentage of Nights With Awakenings Due to Asthma-13.80 ± 27.2-8.20 ± 23.8
SecondaryUse of Rescue Medication at Night

Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.

Time frame:
Daily during run-in and daily during treatment period of 6 weeks
Reported as:
Mean · Inhalations
Use of Rescue Medication at Night
InhalationsWith SpacerWithout Spacer
Use of Rescue Medication at Night-0.21 ± 0.50-0.14 ± 0.38
SecondaryUse of Rescue Medication at Day

Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.

Time frame:
Daily during run-in and daily during treatment period of 6 weeks
Reported as:
Mean · Inhalations
Use of Rescue Medication at Day
InhalationsWith SpacerWithout Spacer
Use of Rescue Medication at Day-0.30 ± 0.56-0.19 ± 0.41

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
With Spacer—0/55 (0%)0/55 (0%)
Without Spacer—0/52 (0%)0/52 (0%)

Baseline characteristics

Age Continuous
Age Continuous(years)With SpacerWithout SpacerTotal
Mean8.6 (6 to 11)8.9 (6 to 11)8.7 (6 to 11)
Sex: Female, Male
Sex: Female, Male(Participants)With SpacerWithout SpacerTotal
Female212243
Male343064
08

Study locations

11 sites
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Kaposvar, Hungary
  • Research Site
    Bialystok, Poland
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Bytom, Poland
  • Research Site
    Karpacz, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Lodz, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Moscow, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2007
First posted
Sep 28, 2007
Start
Sep 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Feb 27, 2012
Last update
Apr 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00536913
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 28, 2007
Start date
Sep 2007
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Feb 27, 2012
Last update
Apr 6, 2012

Study contacts

Tomas Anderson, MD PhD
study director · AstraZeneca
Piotr Kuna, MD PhD
principal investigator · Uniwersytecki Spital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion